Press Release Details

THOUSAND OAKS, Calif., Nov. 11 -- Amgen Inc. (Nasdaq: AMGN) today announced its decision not to commence a registration study in non-Hodgkin's lymphoma and plans to seek another party for the development and commercialization of its rights to epratuzumab. These plans follow a review of the current facts and circumstances regarding the product candidate, Amgen's assessment of its portfolio and other available opportunities. Epratuzumab is currently being developed by Amgen in North America and by Immunomedics, Inc. in Europe for the treatment of indolent and aggressive non-Hodgkin's lymphoma.

About Amgen

Amgen is a global biotechnology company that discovers, develops, manufactures and markets important human therapeutics based on advances in cellular and molecular biology.

Forward-looking Statements

This news release contains forward-looking statements that involve significant risks and uncertainties, including those discussed below and others that can be found in Amgen's Form 10-K for the year ended December 31, 2002, and in Amgen's periodic reports on Form 10-Q and Form 8-K. Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.

No forward-looking statement can be guaranteed and actual results may differ materially from those we project. Amgen's results may be affected by its ability to successfully market both new and existing products domestically and internationally, sales growth of recently launched products, difficulties or delays in manufacturing its products, and regulatory developments (domestic or foreign) involving current and future products and manufacturing facilities. In addition, sales of Amgen's products are affected by reimbursement policies imposed by third party payors, including governments, private insurance plans and managed care providers, and may be affected by domestic and international trends toward managed care and healthcare cost containment as well as possible U.S. legislation affecting pharmaceutical pricing and reimbursement. Government regulations and reimbursement policies may affect the development, usage and pricing of Amgen's products. Furthermore, Amgen's research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. Amgen or others could identify side effects or manufacturing problems with its products after they are on the market.

In addition, Amgen competes with other companies with respect to some of its marketed products as well as for the discovery and development of new products. Discovery or identification of new product candidates cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate will be successful and become a commercial product.

In addition, while Amgen routinely obtain patents for its products and technology, the protection offered by its patents and patent applications may be challenged, invalidated or circumvented by its competitors. Further, some raw materials, medical devices and component parts for Amgen's products are supplied by sole third party suppliers.

    CONTACT:    Amgen, Thousand Oaks
                Trish Hawkins, 805/447- 4587 (media)
                Cary Rosansky, 805/447-1060 (investors)



    NOTE TO EDITORS: An electronic version of this news release may be
accessed via our Web site at www.amgen.com .  Visit the Corporate Center and
click on Amgen News.  Journalists and media representatives may sign up to
receive all news releases electronically at time of announcement by filling
out a short form in the Amgen News section of the Web site.